Articles written in Journal of Biosciences
Volume 43 Issue 5 December 2018 pp 921-929 Article
5rolGLP-HV is a promising dual-function peptide for the treatment of diabetes and thrombosis simultaneously. Forinvestigating the therapeutic mechanism of 5rolGLP-HV for type 2 diabetes mellitus (T2DM), STZ-induced diabetic micewere established and treated with 5rolGLP-HV. The results showed that daily water and food intake, blood glucose, serumand pancreatic insulin levels significantly decreased after 5rolGLP-HV treatment with various oral concentrations, and 16mg/kg was the optimal dose for controlling diabetes. 5rolGLP-HV treatment decreased the MDA levels and the T-SODactivity in serum and pancreatic of diabetic mice (but not up to significant difference), and significantly increased theexpression of signal pathways related genes of rolGLP-1, also the density of insulin expression and the numbers ofapoptosis cells in islets of diabetic mice were significantly decreased in comparison to the negative diabetic mice. Theseeffects above may be clarified the hypoglycemic mechanisms of 5rolGLP-HV, and 5rolGLP-HV may be as a potential drugfor diabetes in future.
Volume 44 Issue 1 March 2019 Article ID 0009 Article
Bio-drug is a new type of beneficial biology expressing therapeutic peptides (protein) as orally administrated medicine totreat diseases, in particular, chronic diseases like diabetes. In order to develop recombinant yeast strains as a bio-drug whichcould effectively ameliorate type 2 diabetes, an integrating expression vector pNK1-PGK that could successfully expressgreen fluorescent protein (GFP) in Saccharomyces cerevisiae was constructed to demonstrate the normality of the function.A pNK1-PGK vector, which expresses 10 tandem repeats of long-acting glucagon-like peptide-1(10laGLP-1), was clonedand then transformed into the S. cerevisiae INVSc1. The long-acting GLP-1 hypoglycemic yeast (LHY168) that grewrapidly and expressed 10laGLP-1 stably was screened by uracil-deficient plates and Western blot. The expression quantityof 10laGLP-1 reached 1.56 mg/g cell wet weight. Moreover, the oral administration of LHY168 significantly declined theblood glucose in type 2 diabetic mice that were constructed through co-induction of streptozotocin (STZ) and high-fat andhigh-sugar diet.
Volume 44 | Issue 5
Click here for Editorial Note on CAP Mode